Trial reportSpinal cord2019
A randomised controlled trial of nasal decongestant to treat obstructive sleep apnoea in people with cervical spinal cord injury.
Trial report in Spinal cord, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Impact of respiratory muscle training on sleep disordered breathing in people with tetraplegia: a sub-analysis of a randomised controlled trial.Spinal cord · 2026Article
- An update on sleep disordered breathing in spinal cord injury.Current opinion in pulmonary medicine · 2025Review
- Overview of the Role of Pharmacological Management of Obstructive Sleep Apnea.Medicina (Kaunas, Lithuania) · 2022Review
- Detection of Sleep-Disordered Breathing in Patients with Spinal Cord Injury Using a Smartphone.Sensors (Basel, Switzerland) · 2021Article
- Impact Of Spinal Cord Injury On Sleep: Current Perspectives.Nature and science of sleep · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
STUDY
designProspective, double-blind, randomised, placebo-controlled, cross-over trial of nasal decongestion in tetraplegia.
objectivesTetraplegia is complicated by severe, predominantly obstructive, sleep apnoea. First-line therapy for obstructive sleep apnoea is nasal continuous positive airway pressure, but this is poorly tolerated. High nasal resistance associated with unopposed parasympathetic activation of the upper airway contributes to poor adherence. This preliminary study tested whether reducing nasal decongestion improved sleep.
settingParticipants' homes in Melbourne and Sydney, Australia.
methodsTwo sleep studies were performed in participants' homes separated by 1 week. Participants were given a nasal spray (0.5 mL of 5% phenylephrine or placebo) in random order and posterior nasal resistance measured immediately. Outcomes included sleep apnoea severity, perceived nasal congestion, sleep quality and oxygenation during sleep.
resultsTwelve middle-aged (average (SD) 52 (12) years) overweight (body mass index 25.3 (6.7) kg/m
conclusionsThese preliminary data found that phenylephrine acutely reduced nasal resistance but did not significantly change sleep-disordered breathing severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.